Cargando…
Adverse Factors of Treatment Response and Overall Survival in Pediatric and Adult Patients with Pineoblastoma
OBJECTIVE: Intracranial pineoblastomas are rare neoplasms with poor prognosis. The aim of this study was to describe the independent prognostic factors and treatment strategies for overall survival in pediatric and adult patients. METHODS: Sixty-four patients were surgically treated between January...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443452/ https://www.ncbi.nlm.nih.gov/pubmed/32884348 http://dx.doi.org/10.2147/CMAR.S258476 |
_version_ | 1783573639025655808 |
---|---|
author | Huo, Xu-Lei Wang, Bo Zhang, Gui-Jun Ma, Jun-Peng Wang, Liang Zhang, Li-Wei Xu, Xiao-Ying Li, Xiao-Jie Li, Huan Li, Da Zhang, Jun-Ting Wu, Zhen |
author_facet | Huo, Xu-Lei Wang, Bo Zhang, Gui-Jun Ma, Jun-Peng Wang, Liang Zhang, Li-Wei Xu, Xiao-Ying Li, Xiao-Jie Li, Huan Li, Da Zhang, Jun-Ting Wu, Zhen |
author_sort | Huo, Xu-Lei |
collection | PubMed |
description | OBJECTIVE: Intracranial pineoblastomas are rare neoplasms with poor prognosis. The aim of this study was to describe the independent prognostic factors and treatment strategies for overall survival in pediatric and adult patients. METHODS: Sixty-four patients were surgically treated between January 2012 and December 2018. RESULTS: The series included 37 (57.8%) males and 27 (42.2%) females. Gross total resection was achieved in 41 (64.1%) cases, and the 1-, 3-, and 5-year rates of overall survival were 86.3, 52.3, and 36.6%, respectively. In the pediatric group (n=42), 28 patients (66.7%) were male, with the median, and the mean age was 4 and 6.2±4.7 years, respectively. After a median follow-up of 25.0 months, twenty-six patients (61.9%) died, and the 1-, 3-, and 5-year rates of overall survival were 84.9, 46.4, and 26.7%, respectively. Postoperative radiotherapy (p=0.058) and postoperative chemotherapy (p=0.183) had a positive influence on the increased overall survival. Meanwhile, postoperative radiotherapy combined with chemotherapy following surgery had a positive impact on overall survival (p=0.174, Log rank). In the adult group, the mean overall survival was 67.3±9.3 months (range, 0.8–95.3 months), and the 1-, 3-, and 5-year rates of overall survival were 89.5, 64.4, and 64.4%, respectively. In this group, no statistical association was observed between clinical factors and outcomes. However, patients who received postoperative radiotherapy (60.7 vs 57.6 month, mean survival; p=0.510, Log rank) or chemotherapy (63.0 vs 59.9 month, mean survival; p=0.404, Log rank) had better survival rates compared with those who declined. CONCLUSION: In the pediatric group, surgery with postoperative radiotherapy and chemotherapy was a favorable factor for overall survival. In the adult group, a positive trend in overall survival was found when patients received radiation and/or chemotherapy following surgery. |
format | Online Article Text |
id | pubmed-7443452 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-74434522020-09-02 Adverse Factors of Treatment Response and Overall Survival in Pediatric and Adult Patients with Pineoblastoma Huo, Xu-Lei Wang, Bo Zhang, Gui-Jun Ma, Jun-Peng Wang, Liang Zhang, Li-Wei Xu, Xiao-Ying Li, Xiao-Jie Li, Huan Li, Da Zhang, Jun-Ting Wu, Zhen Cancer Manag Res Original Research OBJECTIVE: Intracranial pineoblastomas are rare neoplasms with poor prognosis. The aim of this study was to describe the independent prognostic factors and treatment strategies for overall survival in pediatric and adult patients. METHODS: Sixty-four patients were surgically treated between January 2012 and December 2018. RESULTS: The series included 37 (57.8%) males and 27 (42.2%) females. Gross total resection was achieved in 41 (64.1%) cases, and the 1-, 3-, and 5-year rates of overall survival were 86.3, 52.3, and 36.6%, respectively. In the pediatric group (n=42), 28 patients (66.7%) were male, with the median, and the mean age was 4 and 6.2±4.7 years, respectively. After a median follow-up of 25.0 months, twenty-six patients (61.9%) died, and the 1-, 3-, and 5-year rates of overall survival were 84.9, 46.4, and 26.7%, respectively. Postoperative radiotherapy (p=0.058) and postoperative chemotherapy (p=0.183) had a positive influence on the increased overall survival. Meanwhile, postoperative radiotherapy combined with chemotherapy following surgery had a positive impact on overall survival (p=0.174, Log rank). In the adult group, the mean overall survival was 67.3±9.3 months (range, 0.8–95.3 months), and the 1-, 3-, and 5-year rates of overall survival were 89.5, 64.4, and 64.4%, respectively. In this group, no statistical association was observed between clinical factors and outcomes. However, patients who received postoperative radiotherapy (60.7 vs 57.6 month, mean survival; p=0.510, Log rank) or chemotherapy (63.0 vs 59.9 month, mean survival; p=0.404, Log rank) had better survival rates compared with those who declined. CONCLUSION: In the pediatric group, surgery with postoperative radiotherapy and chemotherapy was a favorable factor for overall survival. In the adult group, a positive trend in overall survival was found when patients received radiation and/or chemotherapy following surgery. Dove 2020-08-18 /pmc/articles/PMC7443452/ /pubmed/32884348 http://dx.doi.org/10.2147/CMAR.S258476 Text en © 2020 Huo et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Huo, Xu-Lei Wang, Bo Zhang, Gui-Jun Ma, Jun-Peng Wang, Liang Zhang, Li-Wei Xu, Xiao-Ying Li, Xiao-Jie Li, Huan Li, Da Zhang, Jun-Ting Wu, Zhen Adverse Factors of Treatment Response and Overall Survival in Pediatric and Adult Patients with Pineoblastoma |
title | Adverse Factors of Treatment Response and Overall Survival in Pediatric and Adult Patients with Pineoblastoma |
title_full | Adverse Factors of Treatment Response and Overall Survival in Pediatric and Adult Patients with Pineoblastoma |
title_fullStr | Adverse Factors of Treatment Response and Overall Survival in Pediatric and Adult Patients with Pineoblastoma |
title_full_unstemmed | Adverse Factors of Treatment Response and Overall Survival in Pediatric and Adult Patients with Pineoblastoma |
title_short | Adverse Factors of Treatment Response and Overall Survival in Pediatric and Adult Patients with Pineoblastoma |
title_sort | adverse factors of treatment response and overall survival in pediatric and adult patients with pineoblastoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443452/ https://www.ncbi.nlm.nih.gov/pubmed/32884348 http://dx.doi.org/10.2147/CMAR.S258476 |
work_keys_str_mv | AT huoxulei adversefactorsoftreatmentresponseandoverallsurvivalinpediatricandadultpatientswithpineoblastoma AT wangbo adversefactorsoftreatmentresponseandoverallsurvivalinpediatricandadultpatientswithpineoblastoma AT zhangguijun adversefactorsoftreatmentresponseandoverallsurvivalinpediatricandadultpatientswithpineoblastoma AT majunpeng adversefactorsoftreatmentresponseandoverallsurvivalinpediatricandadultpatientswithpineoblastoma AT wangliang adversefactorsoftreatmentresponseandoverallsurvivalinpediatricandadultpatientswithpineoblastoma AT zhangliwei adversefactorsoftreatmentresponseandoverallsurvivalinpediatricandadultpatientswithpineoblastoma AT xuxiaoying adversefactorsoftreatmentresponseandoverallsurvivalinpediatricandadultpatientswithpineoblastoma AT lixiaojie adversefactorsoftreatmentresponseandoverallsurvivalinpediatricandadultpatientswithpineoblastoma AT lihuan adversefactorsoftreatmentresponseandoverallsurvivalinpediatricandadultpatientswithpineoblastoma AT lida adversefactorsoftreatmentresponseandoverallsurvivalinpediatricandadultpatientswithpineoblastoma AT zhangjunting adversefactorsoftreatmentresponseandoverallsurvivalinpediatricandadultpatientswithpineoblastoma AT wuzhen adversefactorsoftreatmentresponseandoverallsurvivalinpediatricandadultpatientswithpineoblastoma |